Van A Do¹, Rachel D Truong¹, Jacqueline Kropf², Madiha Ahmed¹ and Steve J Carlan³*

¹Department of Internal Medicine, Orlando Regional Medical Center, Orlando, Florida, USA
²Orlando Health, Orlando, Hematology and Oncology, Orlando Health Cancer Institute, Florida, USA
³Academic Affairs and Research, Florida, USA

*Corresponding Author: Steve J Carlan, Academic Affairs and Research, Florida, USA.

Received: May 23, 2023; Published: June 07, 2023

Abstract

Classical Hodgkin lymphoma (cHL) is a highly curable malignancy, even in advanced stage disease with long-term disease specific survival exceeding 85%. Brentuximab vedotin (BV) is an antibody-drug conjugate targeting CD30, is one of the novel therapies that is showing promising results when used in conjunction with frontline treatment for cHL such as doxorubicin. These promising results have been demonstrated since 2018, during which the hallmark ECHELON-1 trial was conducted and eventually led to the approval of BV as part of the initial treatment for advanced stage cHL. A case of a 35-year-old man initially diagnosed with Stage IIB cHL presented with respiratory complications secondary to a large anterior mediastinal mass. The patient was treated with BV in combination with doxorubicin, vinblastine, and dacarbazine (AVD) instead of the first line regiment doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) without complications. This case is unique due to the demonstration of an uncomplicated and exceptional clinical response to BV-AVD in a patient who could not be treated with first-line ABVD due to severe restrictive lung disease and concern for tracheal stenosis.

 Keywords: Classical Hodgkin Lymphoma; Brentuximab Vendotin; BV-AVD; Involved Site Radiation Therapy

Bibliography

1. Shanbhag S and Ambinder RF. “Hodgkin lymphoma: A review and update on recent progress”. CA: A Cancer Journal for Clinicians 2 (2018): 116-132.
2. Vassilakopoulos TP., et al. “Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies”. Cancers 8 (2019): 1071.
3. Tomassetti S, Herrera AF. Update on the role of brentuximab vedotin in classical Hodgkin lymphoma”. Therapeutic Advances in Hematology 9 (2018): 261-272.
4. Connors JM., et al. “Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma”. The New England Journal of Medicine 4 (2018): 331-344.
5. Ansell SM., et al. “Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma”. New England Journal of Medicine4 (2022): 310-320.
6. NCCN Clinical Practice Guidelines in Oncology: Hodgkin Lymphoma. Published online November 8 (2022).
7. Fornecker LM., et al. “Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial”. Journal of Clinical Oncology2 (2023): 327-335.
8. Younes A., et al. “Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation study”. Lancet Oncology13 (2013): 1348-1356.
9. Kumar A., et al. “Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma”. Blood11 (2016): 1458-1464.
10. Montana W., et al. “Near Complete Response in a Patient with Classical Hodgkin Lymphoma Treated with Brentuximab Vedotin Concurrent with Radiation Therapy”. Case Report on Oncology3 (2017): 795-801.

Citation: Steve J Carlan., et al. “Classic Hodgkin Lymphoma Treated with Brentuximab Vedotin". Acta Scientific Clinical Case Reports 4.7 (2023): 03-06.

Copyright: © 2023 Steve J Carlan., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.